Clinical trial · Observational
Real-World Patterns of Utilization of Lenalidomide-based Triplet Regimens in FIrst RElapsed Multiple Myeloma Patients: Evidence From Medical Record Review
NCT07611812CI-TRIAL-00112822completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare progression-free survival (PFS) in patients with first-relapse multiple myeloma treated with Rd-based "triplets" (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs. Elotuzumab + Rd (EloRd) vs. Ixazomib + Rd (IxaRd))
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| First Relpase | — | UNRESOLVED | — |
| Multiple Mieloma | — | UNRESOLVED | — |
| Rd-base Triplet | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Comparison of progression-free survival (PFS) in patients with multiple myeloma at first relapse treated with Rd-based "triplet" regimens (Daratumumab + Rd (DaraRd) vs Carfilzomib + Rd (KRd) vs Elotuzumab + Rd (EloRd) vs Ixazomib + Rd (IxaRd))
- timeFrame
- The study is expected to run for 24 months starting with the enrollment of the first patient in November 2020
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with multiple myeloma (MM) at first relapse treated starting in January 2017 with RD-based triplets in accordance with current clinical practice * Age ≥18 years * Written informed consent signed by the patient Exclusion Criteria: * the patient's refusal to participate
References
Publications (0)
Data not yet available
No reference posted for this study.